United Therapeutics Stock Fundamentals
| UTHR Stock | USD 234.47 0.41 0.18% |
United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.
At this time, United Therapeutics' Income Before Tax is relatively stable compared to the past year. As of 04/24/2024, Net Income is likely to grow to about 1 B, while Total Operating Expenses is likely to drop slightly above 469.6 M. United | Select Account or Indicator |
United Therapeutics Company Return On Equity Analysis
United Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current United Therapeutics Return On Equity | 0.18 |
Most of United Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
United Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, United Therapeutics has a Return On Equity of 0.1827. This is 100.76% lower than that of the Biotechnology sector and 100.5% lower than that of the Health Care industry. The return on equity for all United States stocks is 158.94% lower than that of the firm.
United Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining United Therapeutics's current stock value. Our valuation model uses many indicators to compare United Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across United Therapeutics competition to find correlations between indicators driving United Therapeutics's intrinsic value. More Info.United Therapeutics is rated first in return on equity category among related companies. It is rated first in return on asset category among related companies reporting about 0.61 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for United Therapeutics is roughly 1.63 . At this time, United Therapeutics' Return On Equity is relatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value United Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for United Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the United Therapeutics' earnings, one of the primary drivers of an investment's value.United Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.United Therapeutics is currently under evaluation in return on equity category among related companies.
United Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
United Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.42 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 8.94 B | ||||
| Shares Outstanding | 47.06 M | ||||
| Shares Owned By Insiders | 1.71 % | ||||
| Shares Owned By Institutions | 97.16 % | ||||
| Number Of Shares Shorted | 4.89 M | ||||
| Price To Earning | 23.49 X | ||||
| Price To Book | 1.83 X | ||||
| Price To Sales | 4.70 X | ||||
| Revenue | 2.33 B | ||||
| Gross Profit | 1.78 B | ||||
| EBITDA | 1.39 B | ||||
| Net Income | 984.8 M | ||||
| Cash And Equivalents | 2.26 B | ||||
| Cash Per Share | 49.55 X | ||||
| Total Debt | 700 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 8.10 X | ||||
| Book Value Per Share | 127.23 X | ||||
| Cash Flow From Operations | 978 M | ||||
| Short Ratio | 8.90 X | ||||
| Earnings Per Share | 19.82 X | ||||
| Price To Earnings To Growth | 7.80 X | ||||
| Target Price | 292.25 | ||||
| Number Of Employees | 1.17 K | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 11.01 B | ||||
| Total Asset | 7.17 B | ||||
| Retained Earnings | 6.03 B | ||||
| Working Capital | 2.75 B | ||||
| Current Asset | 1.28 B | ||||
| Current Liabilities | 440.82 M | ||||
| Net Asset | 7.17 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 377 M | 395.8 M | |
| Total Revenue | 2.3 B | 2.4 B | |
| Cost Of Revenue | 257.5 M | 270.4 M | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 0.17 | 0.16 | |
| Research And Ddevelopement To Revenue | 0.18 | 0.17 | |
| Capex To Revenue | (0.1) | (0.10) | |
| Revenue Per Share | 49.73 | 52.22 | |
| Ebit Per Revenue | 0.51 | 0.53 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out United Therapeutics Piotroski F Score and United Therapeutics Altman Z Score analysis. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.626 | Earnings Share 19.82 | Revenue Per Share 49.733 | Quarterly Revenue Growth 0.251 | Return On Assets 0.1122 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.